|
NEWS CENTER
DOR BioPharma 2006 News Archive.
January 4 , 2007
DOR BioPharma Receives $3 Million from Sigma-Tau Pharmaceuticals for Exclusive Right to Negotiate orBec® Strategic Alliance
January 19, 2007
DOR BioPharma Receives Unsolicited Acquisition Proposal from Cell Therapeutics
January 23, 2007
orBec® Pivotal Phase 3 Clinical Trial Results Published in Journal “Blood”.
Results Show Statistically Significant Improvements in Long-Term Survival in Patients with GI GVHD and are Included in DOR’s Pending NDA and MAA Filings
January 24, 2007
DOR BioPharma to Host Conference Call on Thursday, January 25 to Discuss Recently Published orBec® Phase 3 Clinical Results
January 31, 2007
FDA Advisory Committee to Review DOR BioPharma’s orBec® for the Treatment of GI GVHD
February 7 , 2007
DOR BioPharma Sponsors GVHD Working Committee at 2007 Tandem BMT Conference
February 9, 2007
DOR BioPharma Raises $5.5 Million in Private Equity Financing
March 6, 2007
Board of Directors of DOR BioPharma Engages RBC Capital Markets to Evaluate and Negotiate Cell Therapeutics’ Unsolicited Proposal to Acquire DOR.
RBC to also Represent DOR in Connection with Other Potential Third Party Acquirers
March 12, 2007
DOR BioPharma Reviews Year End 2006 Financial Results
March 13, 2007
DOR BioPharma Reports Successful Completion of 1 Year Interim Analysis of RiVaxTM Stability
March 20, 2007
DOR BioPharma Forms orBec® Medical Advisory Board
March 26, 2007
DOR BioPharma Announces FDA Clearance to Conduct Phase 2 Clinical Trial of orBec® for the Prevention of GVHD.
DOR Expands orBec® Pipeline into Other Indications
April 4, 2007
DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide. First Potential Oral Version of Injectable Product
May 7, 2007
DOR BioPharma Announces Release of Advisory Committee Briefing Documents by FDA
May 9 , 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec® for Treatment of GI GVHD Wednesday May 9, 6:00 pm ET.
First GI-Directed Therapy to Treat the Most Common Life Threatening Complication of Allogeneic Hematopoietic Stem Cell Transplantation
May 16, 2007
DOR BioPharma Reports First Quarter 2007 Financial Results.
DOR Reviews Recent Regulatory Events
June 4, 2007
DOR BioPharma to Participate in 5th Annual Biodefense Vaccines & Therapeutics Conference on Monday June 4th
June 22, 2007
DOR BioPharma Adopts Shareholder Rights Plan
June 29, 2007
DOR Appoints Cyrille F. Buhrman to its Board of Directors
July 2, 2007
DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC™
July 12, 2007
DOR BioPharma, Inc. Announces Initiation of orBec® Phase 2 GVHD Prophylaxis Clinical Trial
July 18, 2007
DOR BioPharma, Inc. Announces 3 Month Extension of FDA. PDUFA Action Date for orBec® New Drug Application to Review Supplemental Data
July 30, 2007
DOR BioPharma Announces $940,000 FDA Orphan Products Grant for Clinical Development of RiVax™
August 14, 2007
DOR BioPharma Reports Second Quarter 2007 Financial Results
September 12, 2007
DOR BioPharma Announces Initiation of GI Radiation Injury Program Pursuant to $1 Million NIH Grant
September 17, 2007
orBec® Clinical Review Published in “Expert Review of Clinical Immunology”
September 25, 2007
DOR BioPharma Announces Issuance of Patents for Oral Graft Versus Host Disease
October 2 , 2007
DOR BioPharma Completes Relocation of Corporate Offices to New Jersey
October 09 , 2007
orBec® Clinical Summary Published in “Expert Opinion on Investigational Drugs”
October 19 , 2007
DOR BioPharma Receives Not Approvable Letter from FDA for orBec® for Treatment of Gastrointestinal Graft-vs.-Host Disease. DOR Committed to Addressing Unmet Medical Needs of GVHD Patients. DOR to Host Investor Teleconference at 9AM EDT October 22, 2007
November 14 , 2007
DOR BioPharma Reports Third Quarter 2007 Financial Results
November 15 , 2007
DOR BioPharma Announces CRADA with the Walter Reed Army Institute for Ricin Toxin Vaccine Research
November 28 , 2007
DOR BioPharma Announces Named Patient Access Program for orBec® in Collaboration with Orphan Australia Pty Ltd.
DOR Announces Issuance of Australian Patent for orBec®
December 7 , 2007
DOR BioPharma Announces Results of orBec® End of Review Conference with the FDA
|
